Health Care & Life Sciences » Pharmaceuticals | Akorn Inc.

Akorn Inc. | Income Statement

Fiscal year is January-December. All values USD Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
318
555
985
1,117
841
694
Cost of Goods Sold (COGS) incl. D&A
153
337
455
508
469
501
Gross Income
164
218
530
609
372
193
SG&A Expense
73
124
200
236
272
327
EBIT
91
-
-
372
100
134
Unusual Expense
3
33
36
45
117
254
Non Operating Income/Expense
4
10
5
3
2
1
Interest Expense
9
46
56
54
43
51
Pretax Income
83
25
232
271
59
438
Income Tax
31
11
81
87
35
36
Consolidated Net Income
52
14
151
184
25
402
Net Income
52
14
151
184
25
402
Net Income After Extraordinaries
52
15
151
184
25
402
Net Income Available to Common
52
14
151
184
25
402
EPS (Basic)
0.46
0.13
1.22
1.47
0.20
3.21
Basic Shares Outstanding
96
103
117
123
125
125
EPS (Diluted)
0.46
0.13
1.22
1.47
0.20
3.21
Diluted Shares Outstanding
114
110
126
126
125
125
EBITDA
106
151
416
460
185
52
Equity in Affiliates (Pretax)
-
-
-
-
-
-

About Akorn

View Profile
Address
1925 West Field Court
Lake Forest Illinois 60045
United States
Employees -
Website http://www.akorn.com
Updated 07/08/2019
Akorn, Inc. operates as a niche pharmaceutical company that develops, manufactures and markets generic and prescription pharmaceuticals, as well as, animal and consumer health products. It operates through the Prescription Pharmaceuticals and Consumer Health segments. The Prescription Pharmaceuticals segment engages in the sales of generic and branded prescription pharmaceuticals including ophthalmics, injectables, oral liquids, otics, topicals, inhalants, and nasal sprays.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.